Abstract 2270P
Background
Pancreatic Adenocarcinoma (PAAD) is a highly fatal disease and often associated with a poor prognosis. The development of diabetes mellitus (DM) is an important risk factor. There have been studies exploring markers or prognostic models that affect the prognosis of patients with pancreatic cancer, but there are few studies on pancreatic cancer-associated diabetes mellitus (PCDM) patients.
Methods
The differentially expressed genes (DEGs) between DM and non-DM were detected and selected to build model. PCDM patients were randomly divided into training (70%) and test cohort (30%). Then the univariate COX was performed to screen OS associated genes (p < 0.05) in the training cohort. The LASSO-penalized COX regression and ten-fold cross validation were used to train and select models. The risk score was calculated and verified in both training and test cohort. GSVA, ESTIMATEScore, CIBERSORT and ssGSEA were used to compare the tumor microenvironment (TME). Moreover, the value of genes used in the model was detected on single cell level.
Results
Totally 197 patients (including 60 with DM) were enrolled, 23 genes from DEGs were related to the OS of PCDM patients in the training cohort, and 10 genes were selected to construct the risk model. The risk score for each subject was calculated as follow: risk score=0.434*ACACA+0.119*ATG7+0.373*DEFB123+0.135*FSTL3-0.168*NIPSNAP3B-0.069*RASSF1+0.225*RBPJ+0.364*SLC35F2-0.168*SLC37A1-0.145*ZC3H12D. The C-index was 0.83 in the training cohort (hazard ratio [HR] = 7.61, p < 0.001) and 0.76 in the test cohort (HR = 3.22, p = 0.015). According to the median value -0.054, PCDM patients were split into different risk groups, and patients in the low-risk group showed more enriched T cell related pathways (60 vs 1), higher ImmuneScore (p < 0.001), and more CD8 positive T cell infiltration (CIBERSORT: p < 0.001; ssGSEA: p < 0.001). We calculated the score of genes used in the model in single cells. Malignant cells with the highest score (top 10%) had enhanced activities of angiogenesis.
Conclusions
The prognostic model showed potential value in predicting the OS of patients with PCDM. Patients with low-risk score had a hotter TME and might benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2315P - Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 08
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
2317P - Mutational landscape and therapeutic implications in squamous cell carcinomas
Presenter: Laila Belcaid
Session: Poster session 08
2318P - Value of broad molecular profiling for cancer diagnosis
Presenter: Lars Volker Anton Werstein
Session: Poster session 08
2319P - CADSP: A web tool for comprehensive drug sensitivity analysis in pan-cancer
Presenter: Kexin Li
Session: Poster session 08
2320P - Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Presenter: Peter Horak
Session: Poster session 08
2321TiP - TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
Presenter: Christine Federspiel Secher
Session: Poster session 08
2322TiP - SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Presenter: Jakob Riedl
Session: Poster session 08